<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04459988</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00066792</org_study_id>
    <nct_id>NCT04459988</nct_id>
  </id_info>
  <brief_title>Mechanistic Study of Ocrevus</brief_title>
  <official_title>Enhanced Regulatory Functions of Bregs With Ocrelizumab in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the immune cell and other factor changes with
      Ocrevus in Multiple Sclerosis (MS) patients. Researchers will recruit 35 participants for
      this study. Patients will be enrolled from the Multiple Sclerosis Center at the University of
      Michigan Health System in Ann Arbor. The goal of the study is to understand the role of
      regulatory B cell, T cell and other factors in mediating the therapeutic effects of Ocrevus.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in frequency of regulatory B cells</measure>
    <time_frame>From baseline to 24 months</time_frame>
    <description>Percentage B cells measured by flow cytometry. Compare Ocrevus treatment to baseline and to healthy controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of T cell subtypes</measure>
    <time_frame>From baseline to 24 months</time_frame>
    <description>Percentage of T cells measured by flow cytometry. Compare Ocrevus treatment to baseline and to healthy controls</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Patients with MS</arm_group_label>
    <description>Patients with MS who have been newly prescribed Ocrevus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy Controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ocrelizumab</intervention_name>
    <description>Description Needed</description>
    <arm_group_label>Patients with MS</arm_group_label>
    <other_name>Ocrevus</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood will be collected after 3, 6, 9, 12, 18 and 24 months of treatment.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will recruit 25 MS patients (Group 1; include 5-10 PPMS and 15-20 RRMS).
        Meanwhile, 10 healthy controls (Group 2; HCs) will be recruited to establish baseline
        immune cell profiles. The patients and healthy controls will be recruited at the University
        of Michigan Neurology Clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with MS either with relapsing or primary progressive course; who are newly
        starting on ocrelizumab (Ocrevus) at the time of enrollment

        OR

        Healthy controls who do not have a significant medical conditions such as cancer, chronic
        infection, or autoimmune disease, have not taken steroids in the past 2 months, and who are
        not on an immune suppressant medication.

          -  Ability to give informed consent

          -  Willing to have blood drawn as scheduled in the protocol

          -  Willing and able to complete all procedures and evaluations related to the study

        Exclusion Criteria:

          -  Medical or psychiatric conditions that may affect the patient's ability to give
             informed consent

          -  Has received an experimental drug within 30 days of enrollment

          -  Concomitant other disease modifying medications (such as Rebif, Betaseron, Avonex,
             Copaxone, Gilenya, Tecfidera, Aubagio, Mayzent, Mavenclad, Alemtuzumab, methotrexate,
             azathioprine, Novantrone, cyclophosphamide, cyclosporine, Tysabri, Rituxan, Ocrevus,
             etc.)

          -  Has any contraindication to high-dose immunotherapy, including pregnancy, trying to
             become pregnant, or breast feeding during the study

          -  Active hepatitis B virus infection

          -  History of life-threatening infusion reaction to Rituxan or Ocrevus

          -  Chronic infection or any severe acute infection within 3 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Mao-Draayer, MD/PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Mao-Draayer, MD/PHD</last_name>
    <phone>734-763-3630</phone>
    <email>maodraay@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aiya H Saad, BA</last_name>
    <phone>734-764-8971</phone>
    <email>aiyas@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yang Mao-Draayer, MD/PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Yang Mao-Draayer</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Ocrevus</keyword>
  <keyword>B cell</keyword>
  <keyword>T cell</keyword>
  <keyword>cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocrelizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

